Undisclosed ERVs based cancer vaccine / Evaxion - LARVOL DELTA

Evaxion establishes new AI-derived precision cancer vaccine concept (GlobeNewswire) - "New data confirming the preclinical PoC is presented at the ESMO Immuno-Oncology Congress, currently taking place in Geneva, Switzerland...This precision vaccine concept leverages our unique data insights and expertise in identifying vaccine targets compatible with the diversity of the immune system...The new data prove that the AI-Immunology platform can identify functional and potent ERV antigenic hotspots. This warrants further development towards clinical application...The new data stems from studies in human cell and mouse models. Stimulation with ERV precision vaccine targets induced ERV-specific T-cell responses in human immune cells from several donors. Further, AI-Immunology designed mouse ERV precision vaccines induced functional antigen-specific T-cells and inhibited tumor growth in mice."

Preclinical • Oncology

Evaxion announces 2025 milestones reflecting continued strong strategy execution (GlobeNewswire) - "Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025: All patients completed EVX-01 dosing - H1; Supplemental phase 2 biomarker and immunogenicity data - H1; Two-year phase 2 clinical efficacy readout - H2"

P2 data • Trial status • Melanoma • Oncology • Solid Tumor

Evaxion Announces Business Update and Third Quarter 2023 Financial Results (GlobeNewswire) - "Anticipated 2024 Milestones: (i) EVX-01 – Phase 2 one-year readout, Q3, 2024; (ii) Precision ERV cancer vaccines - Preclinical proof-of-concept obtained, H2, 2024."

P2 data • Preclinical • Melanoma